Important documents
Showing 1 - 10 of 51 results
Report on the annual report on the activities of the European Ombudsman 2012 - Committee on Petitions
Parliament Report - Monday | 15 July 2013
-
Selection of 2012 cases
Overview of cases - Monday | 27 May 2013
The London-based European Medicines Agency (EMA) approves and monitors medicines placed on the EU market, with a view to protecting public health. It receives information concerning suspected adverse reactions to drugs from the national authorities and from pharmaceutical companies. A Greek law firm asked EMA for public access to adverse reaction reports related to a medicine for the treatment of ...
Follow-up to critical and further remarks - How the EU institutions responded to the Ombudsman’s recommendations in 2011
Follow-up - Tuesday | 27 November 2012
The present study explains the purpose of critical remarks and further remarks and the different kinds of circumstance which give rise to them. It analyses the follow-up which the institutions, bodies, offices, and agencies concerned have given to critical remarks and further remarks made in 2011 and identifies ten star cases. It also looks at cases that are particularly significant for the Ombuds...
Report on responses to proposals for friendly solutions and draft recommendations - How the EU institutions complied with the Ombudsman’s suggestions in 2011
Follow-up - Tuesday | 27 November 2012
For five years now, the European Ombudsman has been producing an annual study of the follow-up given by the EU institutions[1] to critical and further remarks made in the preceding year. The follow-up study provides a partial picture of compliance with the Ombudsman's suggestions. It includes cases in which the Ombudsman made a critical remark, following rejection by the institution concerned of a...